An interventional study of Budesonide (400μg/d) and Mometasone Furoate 50mcg Nasal Spray in Chronic Cough (CC), Upper Airway Cough Syndrome and Chronic Rhinitis, sponsored by Silesian University of Medicine. Completed at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-16.
Sponsored by Silesian University of Medicine · Not applicable, Interventional, and Treatment
Chronic cough - a cough lasting eight weeks or longer - is one of the most common reasons people see a lung specialist. It can disturb sleep, make conversation difficult, and reduce quality of life.
In many people, chronic cough occurs together with nose and sinus symptoms such as a blocked or runny nose, mucus dripping down the back of the throat, facial pain, or a reduced sense of smell. This combination is often called upper airway cough syndrome. Doctors commonly treat it with a steroid medicine given either as an inhaler breathed into the lungs or as a spray into the nose. Both are approved, widely used medicines, and treatment guidelines mention both. However, no study has directly compared the two to see whether one relieves cough better than the other, so doctors have little evidence to guide the choice.
This study compares the two treatments directly in adults who have chronic cough together with nose or sinus symptoms. Participants are assigned by chance, like flipping a coin, to one of two groups:
an inhaled steroid (budesonide), breathed in twice a day, or a steroid nasal spray (mometasone furoate), sprayed into each nostril twice a day.
Participants use their assigned treatment for 4 weeks and then return to the clinic. At each visit they rate how severe their cough is by marking a line on a 100-millimetre scale, and they fill in a questionnaire about how the cough affects their daily life.
Participants whose cough has cleared up after 4 weeks finish the study at that point. Those whose cough has not cleared up continue for another 4 weeks: people in the inhaler group carry on with the same inhaler, while people in the nasal spray group continue the spray and also start the inhaler. Everyone who continues returns for a final visit at 8 weeks.
The main question is whether the inhaled steroid reduces cough severity more than the nasal spray after 4 weeks of treatment. The study also looks at cough-related quality of life, and at what happens after treatment is adjusted at 4 weeks.
The study takes place at a single outpatient lung clinic in Katowice, Poland. Both medicines are given at their usual approved doses, and participants are otherwise cared for as in routine practice.
142 studies on the registry are indexed under Chronic Cough; 39 are open to participants now.
This study's enrollment of 56 is close to the median of 60 across 104 interventional studies indexed under Chronic Cough.
Browse Chronic Cough studies →Silesian University of Medicine is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive inhaled budesonide 400 µg per dose, two doses twice daily (800 µg per administration; 1600 µg total daily), for 4 weeks. Cough severity is assessed at the 4-week visit. Participants reaching a Visual Analog Scale score of 10 mm or lower are classified as having achieved cough resolution and complete the study at this point. Participants not reaching this threshold continue inhaled budesonide unchanged at the same dose for a further 4 weeks, to a total of 8 weeks, with a final assessment at week 8.
Drug: Budesonide (400μg/d)
Participants receive intranasal mometasone furoate 50 µg per dose, two doses into each nostril twice daily (100 µg per nostril per administration; 400 µg total daily), for 4 weeks. Cough severity is assessed at the 4-week visit. Participants reaching a Visual Analog Scale score of 10 mm or lower are classified as having achieved cough resolution and complete the study at this point. Participants not reaching this threshold continue intranasal mometasone furoate at the same dose with inhaled budesonide 400 µg per dose, two doses twice daily, added for a further 4 weeks, to a total of 8 weeks, with a final assessment at week 8. Beyond week 4 this arm therefore receives combined intranasal and inhaled corticosteroid therapy rather than intranasal monotherapy.
Drug: Budesonide (400μg/d) · Drug: Mometasone Furoate 50mcg Nasal Spray
Drug page: Budesonide
Inhaled budesonide 400 µg per dose, two doses twice daily (800 µg per administration; 1600 µg total daily), administered by inhaler. In the inhaled corticosteroid arm it is given from randomization as monotherapy for 4 weeks, and continued unchanged at the same dose for a further 4 weeks in participants who have not achieved cough resolution. In the intranasal corticosteroid arm it is added to ongoing intranasal mometasone furoate at week 4 in participants who have not achieved cough resolution, and given for 4 weeks. Maximum total duration of exposure is 8 weeks.
Intranasal mometasone furoate 50 µg per dose, two doses into each nostril twice daily (100 µg per nostril per administration; 400 µg total daily), administered by nasal spray. Given from randomization for 4 weeks. Participants who have not achieved cough resolution at 4 weeks continue it at the same dose for a further 4 weeks with inhaled budesonide added. Maximum total duration of exposure is 8 weeks.
Change from baseline in cough severity measured by Visual Analog Scale (VAS) at 4 weeks
Cough severity is self-rated by the participant on a 100-mm visual analog scale ranging from 0 mm ("no cough") to 100 mm ("worst cough"); higher scores indicate more severe cough. The 4-week score is compared between arms by analysis of covariance with the baseline VAS score as covariate, and reported as an adjusted between-group difference with a 95% confidence interval.
Time frame: Baseline and week 4
Change from baseline in cough severity measured by Visual Analog Scale (VAS) at 8 weeks
Cough severity self-rated on the 100-mm VAS (0 mm = no cough, 100 mm = worst cough; higher scores indicate more severe cough), analysed by the same ANCOVA model as the primary outcome.
Time frame: Baseline and week 8
Change from baseline in cough-related quality of life measured by Leicester Cough Questionnaire (LCQ) total score
The LCQ is a 19-item self-completed questionnaire assessing the impact of cough over the previous 2 weeks across three domains (physical, psychological, social). Each item is scored 1 to 7; the total score is the sum of the three domain means and ranges from 3 to 21, with higher scores indicating better cough-related quality of life. An improvement of 1.3 points is the published minimal important difference.
Time frame: Baseline, 4 weeks and 8 weeks
Proportion of participants achieving therapeutic success
Therapeutic success is defined as a reduction from baseline of 30 mm or more on the 100-mm cough severity VAS, corresponding to the published minimal clinically important difference. Compared between arms with Fisher's exact test and reported as a risk difference with a 95% confidence interval. Exploratory.
Time frame: 4 weeks and 8 weeks
Proportion of participants achieving cough resolution
Cough resolution is defined as a cough severity VAS score of 10 mm or lower. Participants meeting this threshold at 4 weeks complete the study at that visit. Compared between arms with Fisher's exact test and reported as a risk difference with a 95% confidence interval. Exploratory.
Time frame: 4 weeks and 8 weeks
Change from baseline in Leicester Cough Questionnaire (LCQ) domain scores
LCQ physical (8 items), psychological (7 items) and social (4 items) domain scores, each expressed as the mean of its constituent items on a 1 to 7 scale, with higher scores indicating better cough-related quality of life. Published minimal important differences are 0.8 (physical), 0.9 (psychological) and 0.8 (social).
Time frame: Baseline, 4 weeks and 8 weeks
Ran from Jul 2022 to primary completion in Jul 2026, 48 months.
Of 20 interventional studies with no phase under Chronic Cough, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 48. This study's 48 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mometasone Furoate
Silesian University of Medicine